1271 completed, 359 recruiting, 319 unknown, 286 terminated. 1639 Phase 2, 566 Phase 1, 417 Phase 3, 101 Not applicable, 76 Phase 4.
Follow Bevacizumab: new trials by email Literature Review of Bevacizumab trials Research Report on Bevacizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer CA102N, TAS-102, Bevacizumab - Metastatic Colorectal Cancer | Phase 2 | Suspended | Holy Stone Healthcare Co., Ltd | 100 | 2027-12-01 | 2026-09-18 |
| GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors Chimeric Antigen Receptor (CAR) Therapy Infusion, Bevacizumab (Avastin) - Neuroblastoma (NBL), Ewing Sarcoma | Phase 1 | Not yet recruiting | Universität Münster | 30 | 2027-10-01 | 2026-11-03 |
| A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03) R-DXd, Bevacizumab - Fallopian Tube Cancer, Primary Peritoneal Cancer | Phase 3 | Not yet recruiting | Daiichi Sankyo | 600 | 2027-03-31 | 2026-11-13 |
| Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment Transarterial chemoembolization, durvalumab and tremelimumab - HCC, Tace | Phase 2 | Not yet recruiting | Chang Gung Memorial Hospital | 90 | 2027-02-01 | 2026-11-02 |
| Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma | Phase 3 | Recruiting | City of Hope Medical Center | 129 | 2027-01-04 | 2026-11-05 |
| A Phase 2 Study of Bevacizumab Plus Erlotinib in EGFR-Amplified Metastatic Colorectal Cancer Bevacizumab, erlotinib - Metastatic Colorectal Cancer, EGFR Amplified Colorectal Cancer | Phase 2 | Not yet recruiting | Korea University Anam Hospital | 39 | 2027-01-04 | 2026-11-17 |
| Intra-Arterial Bevacizumab as an Adjunct to Middle Meningeal Artery Embolization for Chronic Subdural Hematoma Bevacizumab (intra-arterial) - Chronic Subdural Hematoma | Phase 1 | Not yet recruiting | Dheeraj Gandhi | 18 | 2027-01-01 | 2026-07-27 |
| Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1 INCB123667, Bevacizumab, Placebo - Ovarian Cancer | Phase 3 | Not yet recruiting | Incyte Corporation | 590 | 2026-12-01 | 2026-10-02 |
| Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma NaviFUS System, Lumason, Bevacizumab - GBM | Not applicable | Not yet recruiting | University of Cincinnati | 10 | 2026-12-01 | 2026-06-04 |
| Novel endOvascular Therapy With beVAcizumab and Cannabinoids for Glioblastoma Bevacizumab - GBM | Phase 1 | Not yet recruiting | Unity Health Toronto | 6 | 2026-12-01 | 2026-11-02 |
| Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer varsetatug masetecan, bevacizumab + 5-FU + leucovorin, bevacizumab - Colo-rectal Cancer | Phase 1 / Phase 2 | Not yet recruiting | CytomX Therapeutics | 368 | 2026-12-01 | 2026-10-28 |
| SHR-A2009 Combined With Bevacizumab in the Treatment of Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer : a Randomized Controlled, Open, Multicenter Phase III Study SHR-A2009 + bevacizumab, Sacituzumab Tirumotecan - Non-squamous Non-small Cell Lung Cancer | Phase 3 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 490 | 2026-11-30 | 2026-11-12 |
| A Study of BON-C1393 in Adults With Advanced Solid Tumors BON-C1393, Bevacizumab, Capecitabine - Solid Tumors, Advanced Solid Tumors | Phase 1 | Not yet recruiting | BeOne Medicines | 90 | 2026-11-23 | 2026-11-18 |
| Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP) PRGN-2012, Bevacizumab - Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV) | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 50 | 2026-11-23 | 2026-11-18 |
| A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer Irinotecan, Oxaliplatin, GFH276 - CRC | Phase 1 / Phase 2 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | 150 | 2026-11-15 | 2026-11-06 |
| Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid Tumors QLS5133; Lenvatinib mesylate, QLS5133; QL2107; Lenvatinib mesylate, QLS5133; Bevacizumab - Clear Cell Renal Cell Carcinoma, Ovarian Cancer | Phase 1 / Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 558 | 2026-11-15 | 2026-11-12 |
| Phase II Clinical Study of RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal Cancer RC148 plus Telisotuzumab adizutecan, Telisotuzumab adizutecan plus Bevacizumab - Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy | Phase 2 | Not yet recruiting | RemeGen Co., Ltd. | 412 | 2026-11-01 | 2026-10-26 |
| FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II) Oxaliplatin, 5-Fluorouracil, Levofolinic Acid For Injection - Metastatic Colorectal Cancer (CRC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 229 | 2026-11-01 | 2026-10-16 |
| Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer Rina-S, Bevacizumab - Ovarian Cancer | Phase 3 | Not yet recruiting | Genmab | 602 | 2026-11-01 | 2026-10-05 |
| A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma SHR-8068 + Adebrelimab + Bevacizumab, SHR-8068 Placebo + Adebrelimab Placebo + Bevacizumab Placebo, SHR-8068 Placebo + Adebrelimab + Bevacizumab - Hepatocellular Carcinoma | Phase 3 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 690 | 2026-11-01 | 2026-10-29 |
Showing 20 of 2638. Sign in to see all of them.
Colorectal Neoplasms (487) · Carcinoma, Non-Small-Cell Lung (234) · Breast Neoplasms (197) · Ovarian Neoplasms (189) · Glioblastoma (160) · Carcinoma, Hepatocellular (141) · Neoplasms (130) · Rectal Neoplasms (115) · Colonic Neoplasms (112) · Neoplasm Metastasis (109) · Brain Neoplasms (98) · Lung Neoplasms (96) · Fallopian Tube Neoplasms (94) · Carcinoma, Renal Cell (78) · Glioma (70)
National Cancer Institute (NCI) (161) · Hoffmann-La Roche (156) · M.D. Anderson Cancer Center (76) · Genentech, Inc. (54) · Sun Yat-sen University (46) · Fudan University (40) · SCRI Development Innovations, LLC (32) · Memorial Sloan Kettering Cancer Center (31) · Dana-Farber Cancer Institute (28) · Pfizer (23) · Duke University (21) · Massachusetts General Hospital (21) · Alliance for Clinical Trials in Oncology (20) · ImmunityBio, Inc. (18) · AstraZeneca (17)
United States (1214) · China (520) · France (277) · Spain (249) · Italy (206) · Canada (176) · Germany (176) · South Korea (174) · United Kingdom (152) · Australia (142) · Japan (138) · Taiwan (127) · Belgium (111) · Netherlands (109) · Brazil (91)
Annick Desjardins, MD, FRCPC (7) · Norman Wolmark, MD (7) · Hamid Ahmadieh, MD (6) · John Boockvar, MD (6) · John D. Hainsworth, MD (6)
PMID 37185961, PMID 37146227, PMID 32816630, PMID 33067126, PMID 34616010, PMID 17686822, PMID 21941283, PMID 25098701, PMID 32411431, PMID 37260074, PMID 39777725, PMID 41252656, PMID 10628376, PMID 18024865, PMID 18776057, PMID 19064978, PMID 19097774, PMID 19901100, PMID 20573926, PMID 21383283, PMID 21865400, PMID 22204724, PMID 22204725, PMID 23168366, PMID 24138831, PMID 24637997, PMID 25175099, PMID 25218906, PMID 25240821, PMID 25538173, PMID 26884585, PMID 27501767, PMID 27744512, PMID 27986363, PMID 28237539, PMID 29522361, PMID 30059262, PMID 30293873, PMID 30679026, PMID 30957581, PMID 31101691, PMID 31139483, PMID 31268130, PMID 31276981, PMID 31378656, PMID 32164906, PMID 32278676, PMID 32374423, PMID 32427087, PMID 32997907
2023 (29), 2025 (29), 2008 (22), U10CA180868 (21), U10CA027469 (19), 2017 (18), U10CA021115 (17), 2009 (16), 2015 (14), U10CA032102 (14), 2016 (13), 2014 (12), 2018 (12), U10CA031946 (12), U10CA180820 (12)